BRIEF COMMUNICATION

Hereditary Retinoblastoma and Risk of Lung Cancer

Ruth A. Kleinerman, Robert E. Tarone, David H. Abramson, Johanna M. Seddon, Frederick P. Li, Margaret A. Tucker

Patients who have survived hereditary retinoblastoma are at increased risk of dying of a sarcoma, a melanoma, or a brain tumor. The increased risk has been attributed to germline mutations in the retinoblastoma-1 (RB1) gene, which encodes the cell cycle regulatory protein pRb (1). However, the extent to which patients with hereditary retinoblastoma are at increased risk of dying of common epithelial cancers of adulthood, such as lung cancer, is unknown. Somatic mutations in the RB1 gene are known to contribute to the development of lung cancer(2,3), and evidence of increased risk of lung cancer in adult RB1 mutation carriers has been reported (4,5), but questions remain about the association between hereditary retinoblastoma and lung cancer risk (6). In our earlier follow-up studies of 1604 one-year survivors of retinoblastoma (1,7) followed for a median of 17 years, we did not detect an increased risk of lung cancer, but few patients had reached 40 years of age, when the incidence rates for most epithelial cancers begin to rise. After 7 additional years of follow-up, we have again assessed these patients' risk of dying of lung cancer.

The cohort consists of 964 patients with hereditary retinoblastoma (60%) and 640 patients with nonhereditary retinoblastoma (40%) who were followed from 1 year after retinoblastoma diagnosis in 1914 through 1984 (Table 1). Patients with bilateral tumors or unilateral tumors with a family history of retinoblastoma were classified as having hereditary retinoblastoma. The earlier mortality study (1) was based on followup from 1925 through 1990.

The Institutional Review Board of the National Institutes of Health

Table 1. Selected characteristics of 1604 one-year survivors of retinoblastoma

Characteristic	Hereditary retinoblastoma patients (%)	Nonhereditary retinoblastoma patients (%)	Total (%)
No. of subjects	964 (100)	640 (100)	1604 (100)
Sex			
Male	513 (53.2)	334 (52.2)	847 (52.8)
Female	451 (46.8)	306 (47.8)	757 (47.2)
Age at last follow-up, y			
<40	825 (85.6)	515 (80.5)	1340 (83.5)
≥40	139 (14.4)	125 (19.5)	264 (16.5)
Vital status			
Alive	604 (62.7)	519 (81.1)	1123 (70.0)
Lost to follow-up	51 (5.3)	49 (7.7)	100 (6.2)
Deaths	309 (32.1)	72 (11.3)	381 (23.8)
Cancer deaths*	129 (41.7)†	10 (13.9)†	139 (36.5)†

^{*}Nonretinoblastoma cancer deaths.

(Bethesda, MD) approved this study, in which we linked the cohort with the National Death Index Plus to ascertain new deaths and causes of these deaths through December 31, 1997. Among the patients with hereditary retinoblastoma, 71 females and 68 males had survived to 40 years of age or more by the end of 1997. The standardized mortality ratio (SMR) for the period from 1925 through 1997 was calculated as the ratio of the observed number of deaths among the retinoblastoma patients to the expected number of deaths estimated from the appropriate U.S. age-, sex-, and calendaryear cause-specific death rates (8). Exact 95% confidence intervals (CIs) were computed, assuming that the number of deaths followed a Poisson distribution.

After 7 additional years of follow-up, the risk of death from cancers other than retinoblastoma was higher for patients with hereditary retinoblastoma (observed = 129; expected = 2.75; SMR = 47 [95% CI = 39-56]) than for patients with nonhereditary retinoblastoma (observed = 10; expected = 2.63; SMR = 3.8 [95% CI = 1.8-7.0])(Table 1). During the 7 additional years of follow-up, there were 50 new deaths in the entire cohort attributable to tumors other than retinoblastoma, predominantly cancers of the bone (13 cases), connective tissue (12 cases), and lung (five cases).

Although one case of lung cancer had been reported previously in this cohort (1), subsequent examination of medical records indicates that this cancer, observed in a 12-year-old boy, was probably a metastatic osteosarcoma; therefore, it was excluded from our analyses.

There was a statistically significantly elevated risk of death from lung cancer among patients with hereditary retinoblastoma (observed = 5; expected = 0.33; SMR = 15.2 [95% CI = 4.9– 35]). It is interesting that two lung cancer deaths occurred in patients who received radiotherapy (SMR = 8.1 [95% CI = 1.0-29) and three occurred in patients who did not (SMR = 35 [95% CI]= 7.0–102]), because radiotherapy has been linked with lung cancer in other populations. No lung cancer deaths occurred among patients with nonhereditary retinoblastoma. Histology was available for four of the five lung cancers from the patients with hereditary retinoblastoma (Table 2). Two cancers were small-cell lung carcinomas, one cancer was a mixed small-cell/large-cell carcinoma, and one cancer was an adenocarcinoma.

Several case series and case reports have provided suggestive evidence that lung cancer risk is increased in patients with hereditary retinoblastoma. A case

Affiliations of authors: R. A. Kleinerman, R. E. Tarone, M. A. Tucker, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; D. H. Abramson, New York Presbyterian Hospital–Cornell Medical Center, New York, NY; J. M. Seddon, Massachusetts Eye and Ear Infirmary, Boston; F. P. Li, Division of Cancer Epidemiology and Control, Dana-Farber Cancer Institute, and Harvard School of Public Health, Boston.

Correspondence to: Ruth A. Kleinerman, M.P.H., National Institutes of Health, Executive Plaza South, Rm. 7044, Bethesda, MD 20892 (e-mail: Kleinerr@exchange.nih.gov).

See "Notes" following "References."

© Oxford University Press

[†]Percent of all deaths.

Table 2. Characteristics of lung cancer deaths in a cohort of 1-year survivors of retinoblastoma

Sex	Laterality	Radiotherapy	Lung cancer histology	Age at death, y	Smoking history	Comments
Female	Bilateral	Yes	Unknown	39	60-pack-year smoker	Father, paternal grandfather, and uncle died of lung cancer.
Female	Bilateral	No	Mixed small-cell/large-cell carcinoma	40	19-pack-year smoker	·
Female	Bilateral	Yes	Small-cell carcinoma	40	20-pack-year smoker	Patient was also diagnosed with basal cell carcinoma of the eyelid.
Female	Bilateral	No	Adenocarcinoma	52	Never smoked	Both parents smoked; mother died of lung cancer.
Female	Bilateral	No	Small-cell carcinoma	64	Modest smoker for many years	Patient was also diagnosed with malignant melanoma, basal cell carcinoma of the lip, and leiomyosarcoma of the uterus.

report in 1972 (9) described a small-cell lung cancer in a 45-year-old male who had bilateral retinoblastoma. Among 27 adults who survived retinoblastoma from the Manchester Children's Tumour Registry, there were nine cancer deaths, including four lung cancer deaths in men at the ages of 47, 52, 54, and 56 years (4). Additional case reports noted small-cell lung cancers in a 55-year-old male patient with hereditary retinoblastoma (10) and in a 28-year-old male patient with hereditary retinoblastoma who smoked cigarettes (11).

In addition, in a cohort of 4101 parents, grandparents, aunts, and uncles of British retinoblastoma patients that included 117 RB1 mutation carriers (retinoblastoma survivors or unaffected carriers), the lung cancer SMR for these RB1 mutation carriers was 15.4 (95% CI = 6.6-30) based on eight lung cancer deaths (in four bilateral and two unilateral retinoblastoma survivors and in two unaffected carriers) (5). Including two lung cancer deaths in women that occurred after the study ended, a total of 10 lung cancers were reported in the RB1 mutation carriers (six males and four females; 34 through 62 years of age at diagnosis; six small-cell carcinomas, one adenocarcinoma, and three cancers of unknown histology) (5).

In contrast to these reports, several studies (12–17) have reported no lung cancers in cohorts of retinoblastoma survivors; however, these cohorts have been small or have had few patients followed beyond early adulthood. Studies of relatives of retinoblastoma patients (18–26) have yielded mixed results with respect to non-ocular cancers, with one study (22) suggesting that increased risk of such cancers in retinoblastoma families is due to genetic predisposition independent of RB1 mutations.

Overall, our results, together with earlier reports (4,5), establish that germline RB1 mutations confer an increased risk of lung cancer. The preponderance of males among the previously reported lung cancers in RB1 mutation carriers (i.e., 13 men and four women) suggests that our female excess is a chance occurrence. The relative excess of male lung cancers in the earlier reports [i.e., (4,5,9-11)] probably reflects the much higher smoking rates in men than in women in earlier time periods.

Four of the five women who developed lung cancer during the extended follow-up were cigarette smokers, and the fifth had parents who smoked cigarettes from her birth until she left home; she developed adenocarcinoma, the most frequently observed histologic type of lung cancer in women (27). Small-cell carcinomas are more likely to have somatic mutations or deletions in RB1 (2,28,29), and there was a predominance of small-cell lung histology among the lung cancer patients in our study who smoked (Table 2). Among the 17 RB1 mutation carriers reported previously to have developed lung cancer, smoking information was given for only one patient who was a smoker (11). Histology was reported for 10 patients, and small-cell carcinomas predominated [nine small-cell carcinomas and one adenocarcinoma (5,9-11)], which suggests that the patients may have been smokers.

Lung cancer was diagnosed by 40 years of age in the three heaviest smokers in our study (Table 2). In an earlier study, lung cancer diagnosed before 55 years of age was reported in five first-degree relatives of retinoblastoma patients, and four of these relatives were cigarette smokers (24). The first 610 completed interviews from an ongoing

survey of the retinoblastoma survivors in our study indicate that 45% of the patients with nonhereditary retinoblastoma and 33% of the patients with hereditary retinoblastoma had ever smoked cigarettes and that 24% of the patients with nonhereditary retinoblastoma and 17% of the patients with hereditary retinoblastoma were smoking at last contact, with similar percentages for patients with bilateral and unilateral hereditary retinoblastomas. These smoking rates, which are similar to those of the general population, are surprising in a group that should receive intense medical surveillance. Because smoking rates are not abnormally high in retinoblastoma survivors and no lung cancer deaths were reported for the patients with nonhereditary retinoblastoma, our reported excess of early-onset lung cancers suggests that carriers of RB1 mutations may be highly susceptible to smoking-induced lung cancers. If so, patients with hereditary retinoblastoma should be specially targeted for smoking cessation (30).

REFERENCES

- (1) Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993;85:1121–8.
- (2) Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ, et al. Frequent inactivation of the retinoblastoma antioncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A 1990; 87:2775–9.
- (3) Yandell DW, Poremba C. Genetics of retinoblastoma: implications for other human cancers. Med Pediatr Oncol Suppl 1996;1:25–8.
- (4) Smith JL, Bedford MA. Retinoblastomas. In: Marsden HB, Steward JK, editors. Tumours in children. Berlin (Germany): Springer-Verlag; 1976. p. 245–81.
- (5) Sanders BM, Jay M, Draper GJ, Roberts EM.

- Non-ocular cancer in relatives of retinoblastoma patients. Br J Cancer 1989;60:358–65.
- (6) Haber DA, Fearon ER. The promise of cancer genetics. Lancet 1998;351 Suppl 2:SII1–8.
- (7) Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997; 278:1262–7.
- (8) Monson RR. Analysis of relative survival and proportional mortality. Comput Biomed Res 1974;7:325–32.
- (9) Francois J, Cambie E. Multiple tumors in opthalmology. Ophthalmologica 1972;164:81–3.
- (10) Messmer EP, Richter HJ, Hopping W, Havers W, Alberti W. Non-ocular, malignant secondary tumor following spontaneous healing of a retinoblastoma. Klin Monatsbl Augenheilkd 1987;191:299–303.
- (11) Leonard RC, MacKay T, Brown A, Gregor A, Crompton GK, Smyth JF. Small-cell lung cancer after retinoblastoma [letter]. Lancet 1988;2:1503.
- (12) Abramson DH, Ellsworth RM, Kitchin RD, Tung G. Second nonocular tumors in retinoblastoma survivors. Are they radiationinduced? Ophthalmology 1984;91:1351–5.
- (13) Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986;53:661–71.
- (14) Lueder GT, Judisch GF, O'Gorman TW. Second nonocular tumors in survivors of heritable retinoblastoma. Arch Ophthalmol 1986;104:372–3.
- (15) Winther J, Olsen JH, de Nully Brown P. Risk of nonocular cancer among retinoblastoma patients and their parents. A populationbased study in Denmark, 1943–1984. Cancer 1988;62:1458–62.

- (16) Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 1988:95:1583–7.
- (17) Moll AC, Imhoff SM, Bouter LM, Kuik DJ, Den Otter W, Bezemer PD, et al. Second primary tumors in patients with hereditary retinoblastoma: a register-based follow-up study, 1945–1994. Int J Cancer 1996;67: 515–9.
- (18) Aherne G. Retinoblastoma associated with other primary malignant tumours. Trans Ophthalmol Soc UK 1974;94:938–44.
- (19) Stefani FH. Malignancies in relatives of retinoblastoma patients. Klin Monatsbl Augenheilkd 1976;168:716–8.
- (20) Chan H, Pratt CB. A new familial cancer syndrome? A spectrum of malignant and benign tumors including retinoblastoma, carcinoma of the bladder and other genitourinary tumors, thyroid adenoma, and a probable case of multiple osteosarcoma. J Natl Cancer Inst 1977;58:205–7.
- (21) Fedrick J, Baldwin JA. Incidence of cancer in relatives of children with retinoblastoma. Br Med J 1978;1:83–4.
- (22) Bonaiti-Pellie C, Briard-Guillemot ML. Excess of cancer deaths in grandparents of patients with retinoblastoma. J Med Genet 1980;17:95–101.
- (23) Tarkkanen A, Karjalainen K. Excess of cancer deaths in close relatives of patients with bilateral retinoblastoma. Ophthalmologica 1984;189:143–6.
- (24) Strong LC, Herson J, Haas C, Elder K, Chakraborty R, Weiss KM, et al. Cancer mortality in relatives of retinoblastoma patients. J Natl Cancer Inst 1984;73:303–11.
- (25) Olsen JH, Winther J, Brown PN. Risk of nonocular cancer in first-degree relatives of

- retinoblastoma patients. Hum Genet 1990; 85:283–7.
- (26) Cohen MS, Augsburger JJ, Shields JA, Amsel J, Felberg NT. Cancer in relatives of retinoblastoma patients. Jpn J Ophthalmol 1989;33:173–6.
- (27) Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75(1 Suppl):191–202.
- (28) Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988; 241:353–7.
- (29) Yokota J, Akiyama T, Fung YK, Benedict WF, Namba Y, Hanaoka M, et al. Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 1988;3:471–5.
- (30) Corkery JC, Li FP, McDonald JA, Hanley JA, Holmes GE, Holmes FF. Kids who really shouldn't smoke [letter]. N Engl J Med 1979; 300:1279.

NOTES

Supported in part by Public Health Service contract N01CP81121 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services; and by the Starr Foundation. F. P. Li is a Harry and Elsa Jiler American Cancer Society Clinical Research Professor

We thank Kathy Chimes of Westat, Inc. (Rockville, MD), for data management and Alex Zarechnak of IMS (Silver Spring, MD) for computer support.

Manuscript received July 10, 2000; revised October 2, 2000; accepted October 12, 2000.